Related Experiment Video
Updated: May 31, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers
Ram-Shankar Mani1, Matthew K Iyer, Qi Cao
1Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA.
Abstract:
Recurrent gene fusions involving ETS family genes are a distinguishing feature of human prostate cancers, with TMPRSS2-ERG fusions representing the most common subtype. The TMPRSS2-ERG fusion transcript and its splice variants are well characterized in prostate cancers; however, not much is known about the levels and regulation of wild-type ERG. By employing an integrative approach, we show that the TMPRSS2-ERG gene fusion product binds to the ERG locus and drives the overexpression of wild-type ERG in prostate cancers. Knockdown of TMPRSS2-ERG in VCaP cells resulted in the downregulation of wild-type ERG transcription, whereas stable overexpression of TMPRSS2-ERG in the gene fusion-negative PC3 cells was associated with the upregulation of wild-type ERG transcript. Further, androgen signaling-mediated upregulation of TMPRSS2-ERG resulted in the concomitant upregulation of wild-type ERG transcription in VCaP cells. The loss of wild-type ERG expression was associated with a decrease in the invasive potential of VCaP cells. Importantly, 38% of clinically localized prostate cancers and 27% of metastatic prostate cancers harboring the TMPRSS2-ERG gene fusions exhibited overexpression of wild-type ERG. Taken together, these results provide novel insights into the regulation of ERG in human prostate cancers.
Insights
The TMPRSS2-ERG gene fusion drives overexpression of wild-type ERG in prostate cancer. This overexpression is linked to increased cancer invasiveness, offering new insights into ERG regulation.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Recurrent ETS gene fusions are hallmarks of prostate cancer, with TMPRSS2-ERG being the most prevalent.
- While TMPRSS2-ERG fusion transcripts are understood, the regulation of wild-type ERG in prostate cancer remains unclear.
Purpose of the Study:
- To investigate the regulatory mechanisms of wild-type ERG expression in prostate cancer.
- To determine the functional and clinical significance of wild-type ERG overexpression driven by TMPRSS2-ERG fusions.
Main Methods:
- Integrative analysis of gene expression and genomic data.
- Gene knockdown and overexpression studies in prostate cancer cell lines (VCaP and PC3).
- Analysis of wild-type ERG expression in clinical prostate cancer samples.
Main Results:
- The TMPRSS2-ERG fusion protein binds to the ERG locus, driving wild-type ERG overexpression.
- Knockdown of TMPRSS2-ERG reduced wild-type ERG transcription, while its overexpression increased it.
- Androgen signaling modulates TMPRSS2-ERG, consequently upregulating wild-type ERG.
- Loss of wild-type ERG expression correlated with reduced cellular invasion.
- Overexpression of wild-type ERG was observed in 38% of localized and 27% of metastatic prostate cancers with TMPRSS2-ERG fusions.
Conclusions:
- The TMPRSS2-ERG fusion is a key driver of wild-type ERG overexpression in prostate cancer.
- Wild-type ERG overexpression, regulated by TMPRSS2-ERG and androgen signaling, may contribute to prostate cancer progression and invasiveness.
- These findings elucidate a novel regulatory pathway for ERG in prostate cancer.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
The Ras Gene
Ras is a superfamily...
Mitogens and the Cell Cycle
Master Transcription Regulators
The Unfolded Protein Response

